Drugs / PF-07329640
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06448364 | May → Aug 2024 | colorectal cancer, melanoma, non-small cell lung carcinoma, urothelial carcinoma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07329640 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06448364 ↗ |
| Action | Activate | “an anti-lymphotoxin beta receptor agonist” NCT06448364 ↗ |
| Route | Intravenous | “PF-07329640) as an IV infusion” NCT06448364 ↗ |